연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1501. Clinical performance of anticardiolipin and antiβ2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods.
Chung Y1, Kim JE, Lim HS, Kim HK.
Blood Coagul Fibrinolysis. 2014 Jan;25(1):10-5. doi: 10.1097/MBC.0b013e32836466b5.
Link
1500. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Cha Y, Han SW, Seol H, Oh DY, Im SA, Bang YJ, Park IA, Han W, Noh DY, Kim TY.
Anticancer Res. 2014 Aug;34(8):4275-80
Link
1499. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY.
Oncogene. 2014 Jun 19;33(25):3334-41.
Link
1498. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)
Kim M1, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, Lee JS, Jeon YK, Kim CW, Heo DS.
Ann Hematol. 2014 Oct 11. [Epub ahead of print]
Link
1497. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma.
Kim TM1, Kim S, Ahn YO, Lee SH, Kim DW, Heo DS.
Leuk Lymphoma. 2014 Apr;55(4):940-3. doi: 10.3109/10428194.2013.813505. Epub 2013 Jul 29.
Link
1496. Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.
Paik JH, Nam SJ, Kim TM, Heo DS, Kim CW, Jeon YK1.
BMC Cancer
201412, 14(3) 911
Link
1495. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ1, Go H, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK.
Leuk Lymphoma
201411,55(11)2466-76
Link
1494. Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma
Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, , Se-Hoon Lee, Dae Seog Heo,
Cancer Res Treat 2014; 46(3): 261-269
Link
1493. Immunohistochemical analysis of cyclo- oxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy
Kang HC, Kim IH, Park CI, Park SH
Neuropathology. 2014 Oct;34(5):446-54.
Link
1492. Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Lim YJ, Kim IH, Han TJ, Choi SH, Park SH, Park CK, Paek SH, Lee SH, Kim TM.
Int J Clin Oncol. 2015 Feb;20(1):21-8. doi: 10.1007/s10147-014-0690-6. Epub 2014 Apr 5.
Link